PRESS RELEASE Urgent and accelerated delivery of HIV services is critical to end AIDS by 2030 Gujarat Chief Minister Shri ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...
Researchers suggest that unprotected intercourse, an increase in the number of sexual partners, and changes in testing practices are potential causes.
Located in the heart of a residential community in East Jakarta, the office of Srikandi Sejati Foundation is usually abuzz ...
Life-saving HIV programmes in Lesotho are at risk of collapse following the loss of US foreign aid, more than 30 NGOs warned ...
It was nearly 30 years ago when Rosember Lopez received a life-altering diagnosis: He was HIV positive.With scant ...
GlobalData on MSN18h
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useThe US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a prescription drug user fee act (PDUFA) target action date of ...
In a joint survey by Aidsfonds, GNP+ and the Robert Carr Fund 22% of organizations reported increased experiences of discrimination, including reports of discrimination within healthcare settings, ...
The withdrawal of USAID funding enacted by Donald Trump is having an immediate impact in poor countries – with reproductive ...
The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...
The U.N.'s Angeli Achrekar reports that many clinics have closed, despite exemptions in the policy. She fears mortality will ...
An HIV drug was named “2024 Breakthrough of the Year” by Science Magazine. Biochemistry research from the University of Utah ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback